The curious phenomenon of early cardiac allograft rejection with hepatitis C ‒infected donor heart transplants

In recent years, emerging data have demonstrated that organs from donors infected with hepatitis C virus (HCV) can be transplanted into uninfected recipients with excellent outcomes. Critical to this success is the use of pre-emptive or prophylactic direct-acting anti-viral (DAA) therapy, with the intent to minimize any viral transmission and block viral replication. The optimal timing to employ such therapy, whether at the time of transplantation or after the detection of viremia, remains a matter of ongoing debate.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: EDITORIAL COMMENTARY Source Type: research